These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 24853169)
41. An update on benznidazole for the treatment of patients with Chagas disease. Thakare R; Dasgupta A; Chopra S Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658 [TBL] [Abstract][Full Text] [Related]
42. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Sosa Estani S; Segura EL; Ruiz AM; Velazquez E; Porcel BM; Yampotis C Am J Trop Med Hyg; 1998 Oct; 59(4):526-9. PubMed ID: 9790423 [TBL] [Abstract][Full Text] [Related]
43. Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis. Crespillo-Andújar C; Venanzi-Rullo E; López-Vélez R; Monge-Maillo B; Norman F; López-Polín A; Pérez-Molina JA Drug Saf; 2018 Nov; 41(11):1035-1048. PubMed ID: 30006773 [TBL] [Abstract][Full Text] [Related]
44. Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease. García-Bournissen F; Moroni S; Marson ME; Moscatelli G; Mastrantonio G; Bisio M; Cornou L; Ballering G; Altcheh J Arch Dis Child; 2015 Jan; 100(1):90-4. PubMed ID: 25210104 [TBL] [Abstract][Full Text] [Related]
45. Adverse systemic reaction to benznidazole. Coronel MV; Frutos LO; Muñoz EC; Valle DK; Rojas DH Rev Soc Bras Med Trop; 2017; 50(1):145-147. PubMed ID: 28327820 [TBL] [Abstract][Full Text] [Related]
46. Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease. Frade VP; Moreira CHV; Sabino EC; Bedor DCG; Ghilard FR; Oliveira CDL; Sanches C Rev Inst Med Trop Sao Paulo; 2022; 64():e4. PubMed ID: 35137898 [TBL] [Abstract][Full Text] [Related]
47. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain. Cevey ÁC; Mirkin GA; Penas FN; Goren NB Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474 [TBL] [Abstract][Full Text] [Related]
48. [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation]. Coura JR; de Abreu LL; Willcox HP; Petana W Rev Soc Bras Med Trop; 1997; 30(2):139-44. PubMed ID: 9148337 [TBL] [Abstract][Full Text] [Related]
50. IL-17A, a possible biomarker for the evaluation of treatment response in Trypanosoma cruzi infected children: A 12-months follow-up study in Bolivia. Vásquez Velásquez C; Russomando G; Espínola EE; Sanchez Z; Mochizuki K; Roca Y; Revollo J; Guzman A; Quiroga B; Rios Morgan S; Vargas Ortiz R; Zambrana Ortega A; Espinoza E; Nishizawa JE; Kamel MG; Kikuchi M; Mizukami S; Na-Bangchang K; Tien Huy N; Hirayama K PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007715. PubMed ID: 31553732 [TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole. Watson JA; Strub-Wourgraft N; Tarral A; Ribeiro I; Tarning J; White NJ Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670439 [TBL] [Abstract][Full Text] [Related]
52. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113 [TBL] [Abstract][Full Text] [Related]
53. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole. Teixeira AR; Córdoba JC; Souto Maior I; Solórzano E Am J Trop Med Hyg; 1990 Aug; 43(2):146-58. PubMed ID: 2117856 [TBL] [Abstract][Full Text] [Related]
54. Benznidazole for the treatment of Chagas disease. Losada Galván I; Alonso-Padilla J; Cortés-Serra N; Alonso-Vega C; Gascón J; Pinazo MJ Expert Rev Anti Infect Ther; 2021 May; 19(5):547-556. PubMed ID: 33043726 [TBL] [Abstract][Full Text] [Related]
55. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Fabbro DL; Streiger ML; Arias ED; Bizai ML; del Barco M; Amicone NA Rev Soc Bras Med Trop; 2007; 40(1):1-10. PubMed ID: 17486245 [TBL] [Abstract][Full Text] [Related]
57. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease. Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190 [TBL] [Abstract][Full Text] [Related]
58. Should benznidazole be used in chronic Chagas' disease? Bestetti RB Lancet; 1997 Mar; 349(9052):653. PubMed ID: 9057760 [No Abstract] [Full Text] [Related]
59. Benznidazole prevents endothelial damage in an experimental model of Chagas disease. Molina-Berríos A; Campos-Estrada C; Lapier M; Duaso J; Kemmerling U; Galanti N; Leiva M; Ferreira J; López-Muñoz R; Maya JD Acta Trop; 2013 Jul; 127(1):6-13. PubMed ID: 23529066 [TBL] [Abstract][Full Text] [Related]
60. Treatment with benznidazole in association with immunosuppressive drugs in mice chronically infected with Trypanosoma cruzi: investigation into the possible development of neoplasias. Andrade SG; Mesquita IM; Jambeiro JF; Santos IF; Portella RS Rev Soc Bras Med Trop; 2003; 36(4):441-7. PubMed ID: 12937719 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]